IBJNews

Indiana life sciences upstarts tap health reform booty

Back to TopCommentsE-mailPrintBookmark and Share
On The Beat Industry News In Brief

Many an executive of the state’s life sciences sector hasn’t had much good to say about the federal Patient Protection and Affordable Care Act of 2010—a.k.a. health care reform.

It might as well have been a cussword during a panel discussion at BioCrossroads’ annual meeting this month. For instance, the law assesses pharmaceutical makers $2.3 billion annually and medical-device makers $2 billion a year to help pay for reform.

But a handful of upstart life sciences firms in Indiana aren’t complaining, as they’ll split an aggregate $1.7 million through the Therapeutic Discovery Project Credit, a little-known part of the health care program to help prevent, diagnose and treat chronic illnesses.
 

david johnson Johnson

Receiving notices of funding are at least five firms who’ve previously landed funding from BioCrossroads’ $6 million Indiana Seed Fund: Agene Bio, CS-Keys, FAST Diagnostics, Pericardial Access and Sonarmed.

“They’re all over $100,000. It’s a significant amount for each of those startup companies,” said Lori Leroy, spokeswoman for public-private life sciences initiative BioCrossroads.

The federal credits will add “some very timely fuel to some of our most important development efforts,” BioCrossroads’ president, David Johnson, said in a statement.

“It’s also interesting confirmation, from a credible if somewhat unusual source, that our Indiana Seed Fund is a good judge of breakthrough innovation when it comes to startups.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT